Merck scraps another late-stage Alzheimer's drug study

NEW YORK (Reuters) – Merck & Co Inc on Tuesday said it will end another late-stage trial of an Alzheimer’s drug because it was unlikely to work, adding to the pile-up of failures to find an effective treatment for the mind-wasting disease.


Source: Reuters Medical News

Leave a Reply

Your email address will not be published. Required fields are marked *